Novosibirsk Pharmaceutical Manufacturing Company (PFK) Renewal, which produces 220 names of medicines and occupies up to 3% of the Russian market, intends to increase production 1.5 times, TASS reports with reference to the company’s press service.
The growth is planned to be based on the launch of a new infrastructure, which includes a production workshop and a logistics center. Investments will remain at the level of 2022, that is, up to 3 billion rubles a year, said Vladlen Kalustov, CEO of Renewal. He also said that the company’s sales in 2022 amounted to more than 145 million packages.
Renewal already launched the production of 40 new drugs in 2021 and 50 in 2022, and in 2023 it is planned to release 60 new names of medicines. “We intend to produce generics of imported drugs. And the whole strategy of the company in the coming years is aimed at replacing imported drugs,” said Vladimir Grechkin, the company’s executive director, in 2022.
